MétaCan
Menu
Back to cohort
Record W1977141816 · doi:10.1001/jamaneurol.2014.2157

Rarity of the Alzheimer Disease–Protective<i>APP</i>A673T Variant in the United States

2014· article· en· W1977141816 on OpenAlex
Li-San Wang, Adam C. Naj, Robert Graham, Paul K. Crane, Brian W. Kunkle, Carlos Cruchaga, Josue D. Gonzalez Murcia, Lisa Cannon‐Albright, Clinton T. Baldwin, Henrik Zetterberg, Kaj Blennow, Walter A. Kukull, Kelley M. Faber, Nicole Schupf, Maria C. Norton, JoAnn T. Tschanz, Ronald G. Munger, Christopher Corcoran, Ekaterina Rogaeva, Chiao‐Feng Lin, Beth A. Dombroski, Laura B. Cantwell, Amanda Partch, Otto Valladares, Håkon Håkonarson, Peter St George‐Hyslop, Robert C. Green, Alison Goate, Tatiana Foroud, Regina M. Carney, Eric B. Larson, Timothy W. Behrens, John Kauwe, Jonathan L. Haines, Lindsay A. Farrer, Margaret A. Pericak‐Vance, Richard Mayeux, Gerard D. Schellenberg, Marilyn S. Albert, Roger L. Albin, Liana G. Apostolova, Steven E. Arnold, Robert W. Barber, M. Michael Barmada, Lisa L. Barnes, Thomas G. Beach, James T. Becker, Gary W. Beecham, Duane Beekly, David A. Bennett, Eileen H. Bigio, Thomas D. Bird, Deborah Blacker, Bradley F. Boeve, James D. Bowen, Adam Boxer, James R. Burke, Joseph D. Buxbaum, Nigel J. Cairns, Chuanhai Cao, Chris Carlson, Steven L. Carroll, Helena C. Chui, David G. Clark, David H. Cribbs, Elizabeth Crocco, Charles DeCarli, Steven T. DeKosky, F. Yesim Demirci, Malcolm Dick, Dennis W. Dickson, Ranjan Duara, Nilüfer Ertekin‐Taner, Kenneth B. Fallon, Martin R. Farlow, Steven H. Ferris, Matthew P. Frosch, Douglas Galasko, Mary Ganguli, Marla Gearing, Daniel H. Geschwind, Bernardino Ghetti, John R. Gilbert, Jonathan D. Glass, Neill R. Graff‐Radford, John H. Growdon, Ronald L. Hamilton, Kara L. Hamilton‐Nelson, Lindy E. Harrell, Elizabeth Head, Lawrence S. Honig, Christine M. Hulette, Bradley T. Hyman, Gail P. Jarvik, Gregory A. Jicha, Lee‐Way Jin, Gyungah Jun, M. Ilyas Kamboh, Anna Karydas, Jeffrey Kaye, Ronald Kim, Edward H. Koo, Neil W. Kowall, Joel H. Kramer, Patricia Kramer, Frank M. LaFerla, James J. Lah, James B. Leverenz, Allan I. Levey, Ge Li, Andrew P. Lieberman, Oscar L. López, Kathryn L. Lunetta, Constantine G. Lyketsos, Wendy J. Mack, Daniel Marson, Eden R. Martin, Frank Martiniuk, Deborah C. Mash, Eliezer Masliah, Wayne C. McCormick, Susan M. McCurry, Andrew McDavid, Ann C. McKee, Marsel Mesulam, Bruce L. Miller, Carol A. Miller, Joshua W. Miller, Thomas J. Montine, John C. Morris, Jill R. Murrell, John Olichney, Joseph E. Parisi, William Perry, Elaine R. Peskind, Ronald Petersen, Aimee Pierce, Wayne W. Poon, Huntington Potter, Joseph F. Quinn, Ashok Raj, Murray A. Raskind, Eric M. Reiman, ‌Barry Reisberg, Christiane Reitz, John M. Ringman, Erik D. Roberson, Howard J. Rosen, Roger N. Rosenberg, Mary Sano, Andrew J. Saykin, Julie A. Schneider, Lon S. Schneider, William W. Seeley, Amanda Smith, Joshua A. Sonnen, Salvatore Spina, Robert A. Stern, Rudolph E. Tanzi, Tricia A. Thornton‐Wells, John Q. Trojanowski, Juan C. Troncoso, Debby W. Tsuang, Vivianna M. Van Deerlin, Linda J. Van Eldik, Badri N. Vardarajan, Harry V. Vinters, Jean Paul Vonsattel, Sandra Weıntraub, Kathleen A. Welsh‐Bohmer, Jennifer Williamson, Sarah Wishnek, Randall L. Woltjer, Clinton B. Wright, Steven G. Younkin, Chang‐En Yu, Lei Yu

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
fundA Canadian funder is recorded on the work.

Bibliographic record

VenueJAMA Neurology · 2014
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsOccupational Cancer Research CentreUniversity of Toronto
FundersNIH Clinical CenterNational Center for Research ResourcesNational Cancer InstituteNational Human Genome Research InstituteNational Heart, Lung, and Blood InstituteNational Institute on AgingNational Center for Advancing Translational SciencesMedical Research CouncilCenter for Clinical and Translational Science, University of Alabama at BirminghamLeonard M. Miller School of Medicine, University of MiamiUniversity of California, IrvineNational Institute of Mental HealthFeinberg School of MedicineUniversity of California, San FranciscoCanadian Institutes of Health ResearchUniversity of California, Los AngelesAlzheimer's Disease Research Center, Emory UniversityNational Institutes of HealthUniversity of California, DavisHoward Hughes Medical InstituteEisaiUSF Health Byrd Alzheimer's InstituteNational Institute of Neurological Disorders and StrokeUniversity of PittsburghJohns Hopkins UniversityUniversity of WashingtonUCB PharmaEmory UniversityUniversity of PennsylvaniaUniversity of MiamiYork UniversityPfizerNorthwestern UniversityBiogenMassachusetts General HospitalGenentechUniversity of South FloridaSanofiWellcome TrustUniversity of Southern CaliforniaRush UniversityLeonard M. Miller School of MedicineUniversity of California, San DiegoU.S. Department of Veterans AffairsAstraZenecaEli Lilly and Company
KeywordsCohortAlzheimer's diseaseCase-control studyDiseaseMedicinePopulationGenotypeAllele frequencyGenotypingCohort studyGerontologyInternal medicinePsychologyGeneticsBiologyGene

Abstract

fetched live from OpenAlex

IMPORTANCE: Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States. OBJECTIVE: To determine the frequency of the APP A673T variant in a large group of elderly cognitively normal controls and AD cases from the United States and in 2 case-control cohorts from Sweden. DESIGN, SETTING, AND PARTICIPANTS: Case-control association analysis of variant APP A673T in US and Swedish white individuals comparing AD cases with cognitively intact elderly controls. Participants were ascertained at multiple university-associated medical centers and clinics across the United States and Sweden by study-specific sampling methods. They were from case-control studies, community-based prospective cohort studies, and studies that ascertained multiplex families from multiple sources. MAIN OUTCOMES AND MEASURES: Genotypes for the APP A673T variant were determined using the Infinium HumanExome V1 Beadchip (Illumina, Inc) and by TaqMan genotyping (Life Technologies). RESULTS: The A673T variant genotypes were evaluated in 8943 US AD cases, 10 480 US cognitively normal controls, 862 Swedish AD cases, and 707 Swedish cognitively normal controls. We identified 3 US individuals heterozygous for A673T, including 1 AD case (age at onset, 89 years) and 2 controls (age at last examination, 82 and 77 years). The remaining US samples were homozygous for the alanine (A673) allele. In the Swedish samples, 3 controls were heterozygous for A673T and all AD cases were homozygous for the A673 allele. We also genotyped a US family previously reported to harbor the A673T variant and found a mother-daughter pair, both cognitively normal at ages 72 and 84 years, respectively, who were both heterozygous for A673T; however, all individuals with AD in the family were homozygous for A673. CONCLUSIONS AND RELEVANCE: The A673T variant is extremely rare in US cohorts and does not play a substantial role in risk for AD in this population. This variant may be primarily restricted to Icelandic and Scandinavian populations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.061
Threshold uncertainty score0.307

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.289
Teacher spread0.264 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it